Pharmaco-economics of levosimendan in cardiology: A European perspective.

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Nieminen, Markku Sakarica
• dc.contributor.author Buerke, Michaelca
• dc.contributor.author Parissis, Johnca
• dc.contributor.author Ben-Gal, Tuviaca
• dc.contributor.author Pollesello, Pieroca
• dc.contributor.author Kivikko, Mattica
• dc.contributor.author Karavidas, Apostolosca
• dc.contributor.author Severino, Paoloca
• dc.contributor.author Comín Colet, Josepca
• dc.contributor.author Wikström, Gerhardca
• dc.contributor.author Fedele, Frencescoca
• dc.date.accessioned 2015-11-05T11:36:06Z
• dc.date.available 2015-11-05T11:36:06Z
• dc.date.issued 2015
• dc.description.abstract INTRODUCTION: Heart failure places a significant economic burden on health care. Acute heart failure requires hospitalization and often frequent re-hospitalization in expensive wards where vasoactive rescue therapy is often added on top of standard medications. In these lean times, there is a growing need for cost-effective therapeutic options that supply superior support and in addition shorten the length of stay in hospital and reduce re-hospitalization rates. The inodilator levosimendan represents the latest addition to the vasoactive treatments of acute heart failure patients, and it appears to meet these expectations. Our aim was to answer the question whether the treatment efficacy of levosimendan - when selected as therapy for patients hospitalized for acute heart failure - brings savings to hospitals in various European countries representing different economies. METHODS AND RESULTS: We took a conservative approach and selected some a fortiori arguments to simplify the calculations. We selected seven European countries to represent different economies: Italy, Spain, Greece, Germany, Sweden, Finland and Israel. Data on the costs of medications and on the cost per day were collected and fed in a simple algorithm to detect savings. These saving varied from country to country, from a minimum of €0.50 in Germany to a maximum of €354.64 in Sweden. CONCLUSIONS: The use of levosimendan as a therapy for patients hospitalized for acute heart failure provides a net saving to hospitals driven by a reduction in the length of hospital stay. This finding is true in each of the countries considered in this study.ca
• dc.format.mimetype application/pdfca
• dc.identifier.citation Nieminen MS, Buerke M, Parissis J, Ben-Gal T, Pollesello P, Kivikko M. et al. Pharmaco-economics of levosimendan in cardiology: A European perspective. Int J Cardiol. 2015 Nov 15;199:337-41. doi: 10.1016/j.ijcard.2015.07.049.ca
• dc.identifier.doi http://dx.doi.org/10.1016/j.ijcard.2015.07.049
• dc.identifier.issn 0167-5273
• dc.identifier.uri http://hdl.handle.net/10230/25004
• dc.language.iso engca
• dc.publisher Elsevierca
• dc.relation.ispartof International Journal of Cardiology. 2015 Nov 15;199:337-41
• dc.rights 0167-5273/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ca
• dc.rights.accessRights info:eu-repo/semantics/embargoedAccessca
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ca
• dc.subject.other Infart de miocardica
• dc.title Pharmaco-economics of levosimendan in cardiology: A European perspective.ca
• dc.type info:eu-repo/semantics/articleca
• dc.type.version info:eu-repo/semantics/publishedVersionca